Clean Science Q2 Revenue Up 23% YoY Consolidated

Trading Symbol

CLEAN (NSE)

Subject

Investor Presentation for Quarter and Half Year ended 30th September, 2026

This document is an investor presentation for Q2 and H1 FY2027, submitted to the stock exchanges in compliance with SEBI Listing Regulations (Regulation 30 read with Schedule III).

Q2 FY2027 Business Update

The company reported progressive revenue growth supported by a new segment, though margins were moderated due to geopolitical headwinds.
Total capital expenditure of approximately ₹150 crores was incurred during H1 FY2027. This investment was directed towards Clean Fino Chem Ltd. (CFCL), a wholly-owned subsidiary of CSTL.
CFCL completed advanced HALS (Hindered Amine Light Stabilizers) product trials with Geneus Chem AG, meeting quality and regulatory standards. A commercial launch is expected in the second half of FY2026–27.
Another product, referred to as "Performance Chemical 2," is also expected to be commercialized in H2 FY27.

Financial Performance (Q2 FY2027)

Consolidated Results:

Revenue from Sale of Products: ₹295 crore, up 23% YoY (Q2 FY26: ₹240 crore) and 12% QoQ (Q1 FY27: ₹264 crore).
Total Revenue: ₹299 crore, up 22% YoY.
Raw Material Expenses: ₹128 crore (43.3% of sales), up 33% YoY.
EBITDA: ₹92 crore, up 5% YoY. EBITDA margin stood at 31.2%, down from 36.4% in Q2 FY26.
Profit Before Tax (PBT): ₹74 crore, down 1% YoY. PBT margin was 25.2%.
Profit After Tax (PAT): ₹56 crore, nearly flat (0.5% growth) YoY. PAT margin was 18.9%.

Standalone Results:

Revenue from Sale of Products: ₹226 crore, up 10% YoY.
EBITDA: ₹82 crore, down 9% YoY. EBITDA margin was 36.3%.
PAT: ₹55 crore, down 14% YoY. PAT margin was 24.5%.

Financial Performance (H1 FY2027)

Consolidated Results:

Revenue from Sale of Products: ₹559 crore, up 17% YoY (H1 FY26: ₹480 crore).
Total Revenue: ₹568 crore, up 16% YoY.
EBITDA: ₹188 crore, up 1% YoY. EBITDA margin was 33.7%.
PAT: ₹129 crore, up 3% YoY. PAT margin was 23.1%.

Standalone Results:

Revenue from Sale of Products: ₹430 crore, up 2% YoY.
EBITDA: ₹169 crore, down 11% YoY. EBITDA margin was 39.3%.
PAT: ₹129 crore, down 9% YoY. PAT margin was 29.9%.

Balance Sheet Overview (As of 30th September 2026)

Standalone:

Total Assets: ₹1,919 crore (Mar-26: ₹1,784 crore).
Net Worth: ₹1,733 crore (Mar-26: ₹1,646 crore).
Fixed Assets: ₹317 crore; Capital Work-in-Progress: ₹11 crore.
Investments: ₹265 crore (Mar-26: ₹343 crore).
Inventories: ₹142 crore (Mar-26: ₹102 crore).
Trade Receivables: ₹190 crore (Mar-26: ₹149 crore).
The company remains a zero-debt entity.

Consolidated:

Total Assets: ₹1,920 crore (Mar-26: ₹1,783 crore).
Net Worth: ₹1,672 crore (Mar-26: ₹1,584 crore).
Fixed Assets: ₹701 crore; Capital Work-in-Progress: ₹156 crore (Mar-26: ₹118 crore).
Investments: ₹350 crore.
Inventories: ₹221 crore (Mar-26: ₹154 crore).
Trade Receivables: ₹263 crore (Mar-26: ₹206 crore).

Operational and Strategic Highlights

The HALS segment grew 2x during H1 FY27 on the back of higher volumes.
The company successfully de-risked its product concentration. The contribution of the top four legacy products declined from ~85% in Q4 FY23 to ~58% in Q2 FY27. The HALS segment now accounts for 22% of sales.
The company has 4 manufacturing units, over 500 global customers across 35+ countries, and 61% of consolidated revenue comes from exports.
It has a strong R&D focus with 65+ scientists across 4 facilities.
The company highlighted its commitment to ESG, including a 15% reduction target for GHG emissions, specific water consumption, and specific energy consumption over 5 years starting 2023. It has a 20 MW solar capacity, with renewable energy accounting for 65% of power consumption.
CSR contributions over the last 3 years totaled over ₹21 crore.
The company has a CRISIL long-term rating of AA- (Stable) and a short-term rating of A1+.

Corporate Contacts

For further information, contact Pratik Bora at pratik@cleanscience.co.in.
The presentation is also available on the company's website.